Arrowhead Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HDP1.F | IONS | ALNY | ADRX | MAZE | BBIO | |
|---|---|---|---|---|---|---|
| Market cap | 7.47B | 7.41B | 30.13B | 1.83B | 1.81B | 13.26B |
| P/E (TTM) | — | — | 38.0 | — | — | — |
| Forward P/E | -110.2 | -40.1 | 18.2 | -11.3 | -10.1 | -302.0 |
| Price/book | 18.0 | 16.8 | 22.2 | -0.8 | 4.0 | -5.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +61.58% | −36.50% | −50.37% | −8.63% | +11.44% | +26.88% |
| Today | +1.11% | −1.85% | −2.39% | −2.88% | +0.68% | +0.41% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All HDP1.F news ›Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head Review
Posted by Danessa Lincoln on Oct 18th, 2026 Sera Prognostics (NASDAQ:SERA – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast…
UBS Group Upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “Strong-Buy”
Posted by Kim Johansen on Oct 17th, 2026 Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a report issued on Wednesday, Zacks reports. View Our Latest…
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Posted by Defense World Staff on Oct 17th, 2026 DBV Technologies (NASDAQ:DBVT – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast…
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform
(NASDAQ:ARWR) Seeking Alpha - Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. - ARWR plans to expand its CNS…
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline October 14, 2026 2:30 PM EDT Vincent Anzalone - Head of Investor Relations & VPDr. Christopher…
Arrowhead Pharmaceuticals reports strong ARO-MAPT phase 1 results, plans multiple CNS trials by 2027
Arrowhead Pharmaceuticals exceeded expectations with its ARO-MAPT phase 1 trial, achieving up to 85% reduction in CSF tau protein, validating its CNS siRNA platform. The company plans to expand its central nervous system (CNS) pipeline by…
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
BioSpace Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers - Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that…
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/dL…
Arrowhead Pharmaceuticals, Inc. : Insider Transactions
Follow insider transactions on Arrowhead Pharmaceuticals, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Arrowhead Pharmaceuticals, Inc. Biotechnology & Medical…
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
Presentation Operator MessageOperator Good morning, everyone, and welcome to the Arrowhead Pharmaceuticals Investor Webcast. [Operator Instructions] As a reminder, this call is being recorded, and Transcript : Arrowhead Pharmaceuticals,…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com10
-
seekingalpha.com4
-
news.alphastreet.com2
-
stocktitan.net2
-
themarketsdaily.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.